v3.25.2
EPS Calculation (Tables)
6 Months Ended
Jun. 30, 2025
Earnings Per Share [Abstract]  
Schedule of Reconciliation of the (Loss)/Earnings and Shares used in Calculating Basic and Diluted EPS
The following table presents a reconciliation of the earnings/(loss) and shares used in calculating basic and diluted earnings/(loss) per share for the three and six months ended June 30, 2025 and 2024:
 
Three Months Ended
June 30,
Six Months Ended
June 30,
(In Thousands, Except Per Share Amounts)2025202420252024
Basic Earnings/(Loss) per Share:
Net income/(loss) to common stockholders$33,184 $41,946 $74,360 $65,159 
Dividends declared on preferred stock(10,560)(8,218)(18,779)(16,437)
Dividends, dividend equivalents and undistributed earnings allocated to participating securities(200)(114)(406)(281)
Net income/(loss) attributable to common stockholders - basic$22,424 $33,614 $55,175 $48,441 
Basic weighted average common shares outstanding103,705 103,446 103,740 103,310 
Basic Earnings/(Loss) per Share$0.22 $0.32 $0.53 $0.47 
Diluted Earnings/(Loss) per Share:
Net income/(loss) to common stockholders - basic$22,424 $33,614 $55,175 $48,441 
Dividends, dividend equivalents and undistributed earnings allocated to participating securities— — — — 
Interest expense on Convertible Senior Notes— — — — 
Net income/(loss) attributable to common stockholders - diluted$22,424 $33,614 $55,175 $48,441 
Basic weighted average common shares outstanding103,705 103,446 103,740 103,310 
Unvested and vested restricted stock units1,602 1,730 1,536 1,643 
Effect of assumed conversion of Convertible Senior Notes to common shares— — — — 
Diluted weighted average common shares outstanding (1)
105,307 105,176 105,276 104,953 
Diluted Earnings/(Loss) per Share$0.21 $0.32 $0.52 $0.46 
(1)At June 30, 2025 and 2024, the Company had approximately 931,000 and 341,000 equity instruments outstanding that were excluded from the calculation of diluted EPS for the three and six months ended June 30, 2025 and 2024, as they were determined to be anti-dilutive. These equity instruments reflect RSUs (based on current estimate of expected share settlement amount) with a weighted average grant date fair value of $10.45 and $11.20, respectively. These equity instruments may have a dilutive impact on future EPS.